Patents by Inventor Silvina Garcia-Rubio

Silvina Garcia-Rubio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9872883
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 23, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9751836
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 5, 2017
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Claudio Pietra, Claudio Giuliano, Zhigang Li
  • Publication number: 20170145038
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 2, 2016
    Publication date: May 25, 2017
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Patent number: 9546157
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: January 17, 2017
    Assignee: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Publication number: 20160235804
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicants: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20160237115
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicants: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20160229889
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 11, 2016
    Applicants: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9403867
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 2, 2016
    Assignees: Ono Pharmaceuticals Co., Ltd., Helsinn Healthcare SA
    Inventors: Shin-Itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20150252021
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 6, 2015
    Publication date: September 10, 2015
    Applicant: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Publication number: 20150072934
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Applicants: Ono Pharmaceutical Co., Ltd., Helsinn Healthcare SA
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Marcia Philipson, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20140121210
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Applicant: HELSINN HEALTHCARE SA
    Inventors: Silvina GARCIA RUBIO, Claudio PIETRA, Claudio GIULIANO, Zhigang LI
  • Patent number: 8658797
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 25, 2014
    Assignee: Helsinn Healthcare SA
    Inventors: Silvina Garcia Rubio, Claudio Giuliano, Claudio Pietra, Zhigang Li
  • Publication number: 20140018391
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 18, 2013
    Publication date: January 16, 2014
    Applicants: Ono Pharmaceutical Co., Ltd., Helsinn Healthcare SA
    Inventors: Marcia Philipson, Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuko Yoshiyama, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20120220629
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Inventors: Silvina GARCIA RUBIO, Claudio Pietra, Claudio Giuliano, Zhigang Li
  • Publication number: 20100317581
    Abstract: Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin; b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7; c) optionally from 0.1 to 30% of one or more formulation aids; and d) water q.s. to 100%; all percentages based on the total weight of the solution.
    Type: Application
    Filed: June 8, 2010
    Publication date: December 16, 2010
    Applicant: Helsinn Therapeutics (U.S.), Inc.
    Inventors: Silvina Garcia Rubio, Daniel E. Beidler, Helle Weibel, Riccardo Braglia
  • Publication number: 20100029941
    Abstract: Described herein are methods for making chiral derivatives of 3-aminopiperidine, including the production of such derivatives in quantities exceeding 1 kilogram. The chiral 3-aminopiperidine derivatives include (R)-3-aminopiperidine derivatives which may be used to synthesize inhibitors of Dipeptidyl Peptidase IV. (R)-3-Aminopiperidine dihydrochloride is prepared by reducing (R)-3-aminopiperidin-2-one hydrochloride with lithium aluminum hydride. The preparation of (R)-3-aminopiperidin-2-one hydrochloride starting from (R)-methyl-2,5-diaminopentanoate dihydrochloride or (R)-2,5-diaminopentanoic acid hydrochloride is also described.
    Type: Application
    Filed: March 26, 2007
    Publication date: February 4, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Michael B. Wallace, Jeremy Cody, Richard S. Fornicola, Silvina Garcia-Rubio, Philip B. Kisanga, Maxwell D. Reeve, Chandra Wilson